Importance of dose in palliative treatment for incurable head and neck cancer with radiotherapy. Issue 3 (15th December 2020)

• Record Type: Journal Article
• Authors: García‐Anaya, María J.; Ordoñez, Rafael; Toledo, María D.; Correa, Raquel C.; Otero, Ana; Román, Alicia; García‐Ríos, Isabel; Medina, José A.; Gómez‐Millán, Jaime
• Is Part Of: Head & neck. Volume 43:Issue 3(2021)
• Page Start: 798
• Page End: 804
• Publication Date: 2020-12-15
• Subjects: head and neck cancer -- hypo trial -- hypofractionated -- palliative care -- radiation therapy; Head -- Diseases -- Periodicals; Neck -- Diseases -- Periodicals; Head -- Periodicals; Neck -- Periodicals; Face -- Periodicals; 617.51059
• DOI: 10.1002/hed.26555
• Languages: English
• ISSNs: 1043-3074

Abstract

Abstract: Purpose: To identify predictors of palliation for head and neck cancer treated with the "Hypo Trial" hypofractionated radiation therapy regimen in a clinical setting. Design/Method: We retrospectively assessed 106 consecutive patients with incurable cancer, treated between January 2008 and December 2018. Regimen used was 30‐36Gy in 5‐6 biweekly fractions of 6Gy. Results: The prescription dose was 30Gy in 57 (53.8%) patients and 36Gy in 49 (46.2%) patients. 89.6% patients completed the prescribed treatment. With a median follow‐up of 6.92 months, 79.2% of the patients experienced clinical palliation. Palliation was correlated with the radiation therapy dose ( P = 0.05). Median overall and progression‐free survival (OS, PFS) were 7 and 4.63 months, respectively. Achieving palliation was associated to OS ( P = 0.01). Conclusions: This short palliative hypofractionated scheme resulted in a high rate of palliation, with excellent compliance and acceptable toxicity. Our results show that radiation dose is a predictive factor for palliation.